Thus, novel immunotherapeutic strategies aimed at blocking the interaction of PD-1 and CTLA-4 with their ligands, paralleled by the targeting of HLA-G/ILT2 interaction, may greatly enhance the rescue of anti-tumor immune response. This evidence concerns the gene HLA-G and neoplasm.